Edesa Biotech (EDSA) Gross Margin (2013 - 2020)

Edesa Biotech (EDSA) posted Gross Margin of 362.8% for Q3 2020, down 467.72% sequentially from 98.66% in Q2 2020.

Edesa Biotech (EDSA) Gross Margin (2013 - 2020) Analysis & Trends

Edesa Biotech has reported Gross Margin for 8 years, with the latest figure at 362.8% in Q3 2020.

Quarterly Gross Margin changed N/A year-over-year to 362.8% in Q3 2020, while the trailing twelve-month figure through Jun 2021 was 362.8% (down 45815.0% YoY) and the FY2020 annual result came in at 94.65%, up 1930.0% from the prior year.
Gross Margin retreated to 362.8% in Q3 2020 per EDSA's latest filing, from 98.66% in the prior quarter.
Over five years, Gross Margin peaked at 132.41% in Q3 2017 and troughed at 378.6% in Q4 2017.
A 5-year average of 20.15% and a median of 59.68% in 2016 frame the typical range for Gross Margin.
The sharpest annual moves came in 2016 and 2017: Gross Margin jumped 14617 bps in 2016, then plunged 41879 bps in 2017.
Over 5 years, Gross Margin stood at 40.2% in 2016, then plunged by 1042 bps to 378.6% in 2017, then surged by 96 bps to 16.19% in 2018, then jumped by 696 bps to 96.5% in 2019, then slumped by 476 bps to 362.8% in 2020.
According to Business Quant data, Gross Margin over the past three periods registered 362.8%, 98.66%, and 90.92% for Q3 2020, Q2 2020, and Q1 2020 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	90.43%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	76.90%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	84.20%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	63.27%
10	Edesa Biotech	43.15 Mn	43.15 Mn	-	-

Download Data